Lithium's Antiviral Effects: a Potential Drug for Covid-19 Disease?

Total Page:16

File Type:pdf, Size:1020Kb

Lithium's Antiviral Effects: a Potential Drug for Covid-19 Disease? Murru et al. Int J Bipolar Disord (2020) 8:21 https://doi.org/10.1186/s40345-020-00191-4 REVIEW Open Access Lithium’s antiviral efects: a potential drug for CoViD-19 disease? Andrea Murru1†, Mirko Manchia2,3,4†, Tomas Hajek5, René E. Nielsen6,7, Janusz K. Rybakowski8,9, Gabriele Sani10,11, Thomas G. Schulze12,13,14,15,16, Leonardo Tondo17,18,19, Michael Bauer20* and for the International Group for The Study of Lithium Treated Patients (IGSLi) Abstract Background: Since its introduction in modern medicine, naturalistic observations emerged about possible uses of lithium treatment for conditions diferent from recurring afective disorders, for which it is still a frst-line treatment option. Some evidence about the antiviral properties of lithium began in the early 1970s, when some reports found a reduction of labial-herpetic recurrences. The present review aims to present most of the pre-clinical and clinical evi- dence about lithium’s ability to inhibit DNA and RNA viruses, including Coronaviridae, as well as the possible pathways and mechanisms involved in such antiviral activity. Main body: Despite a broad number of in vitro studies, the rationale for the antiviral activity of lithium failed to translate into methodologically sound clinical studies demonstrating its antiviral efcacy. In addition, the tolerability of lithium as an antiviral agent should be addressed. In fact, treatment with lithium requires continuous monitoring of its serum levels in order to prevent acute toxicity and long-term side efects, most notably afecting the kidney and thyroid. Yet lithium reaches heterogeneous but bioequivalent concentrations in diferent tissues, and the anatomical compartment of the viral infection might underpin a diferent, lower need for tolerability concerns which need to be addressed. Conclusions: Lithium presents a clear antiviral activity demonstrated at preclinical level, but that remains to be con- frmed in clinical settings. In addition, the pleiotropic mechanisms of action of lithium may provide an insight for its possible use as antiviral agent targeting specifc pathways. Keywords: Bipolar disorder, GSK-3β, Inositol, Virus, Coronavirus Background Grof 2018) to elder populations (Young et al. 2017). In More than 70 years since introduction to routine clini- addition to its established clinical efcacy, lithium is cal practice, lithium remains the frst-line option for the associated with a reduction of suicide risk (Tondo and treatment of bipolar disorder (BD), having the strongest Baldessarini 2018), which is exerted irrespective of its evidence supporting both its acute and long-term ef- mood-stabilizing properties (Manchia et al. 2013; Sarai cacy in patients with BD (Yatham et al. 2018). Indications and Mekala 2018) and possibly at concentrations as low for use of lithium in BD span across diferent age groups, as those found in drinking water (Barjasteh-Askari et al. from children/adolescents (Dufy et al. 2018; Dufy and 2020). Importantly, lithium contributes to reduction of depressive morbidity, which is predominant in the clini- *Correspondence: [email protected] cal course of BD (Murru et al. 2017a; Samalin et al. 2016), †Andrea Murru and Mirko Manchia contributed equally to this work and is associated with an excess of mortality (Baldessarini 20 Department of Psychiatry and Psychotherapy, University Hospital et al. 2020). Carl Gustav Carus, Medical Faculty, Technische Universität Dresden, Fetscherstr. 74, 01307 Dresden, Germany Despite the well-established efcacy of lithium, its Full list of author information is available at the end of the article use has declined in the last decades in some parts of the © The Author(s) 2020. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://crea- tivecommons.org/licenses/by/4.0/. Murru et al. Int J Bipolar Disord (2020) 8:21 Page 2 of 9 world, partly due to the safety concerns, which require RNA virus, facilitating the accumulation of newly syn- proper therapeutic monitoring, and to strong market- thesized DNA inside the capsid (Mallery et al. 2018). ing strategies supporting the use of anticonvulsants and It is conceivable that decreased levels of IP6 would antipsychotics, which however may be less efective decrease the ability of HIV of replicating efectively. (Tondo et al. 2019). Recent evidence shows that the renal Replicated data show that lithium promotes autophagy, toxicity and teratogenic efects of lithium are much less the physiological process responsible for the quality con- pronounced than initially thought (Fornaro et al. 2020; trol of essential cellular components by purging the cell Nielsen et al. 2018). of old or damaged organelles in several neuropsychiatric conditions (Motoi et al. 2014). Te benefcial efect of Lithium molecular efects lithium on autophagy has been demonstrated in several Lithium has a pleiotropic mechanism of action modulat- neurodegenerative disorders, including Huntington’s dis- ing frst, second and third messengers (and their down- ease (Sarkar et al. 2005) and amyotrophic lateral sclerosis stream molecular cascades),higher order biological (Fornai et al. 2008) and it appears to be mediated through systems (Alda 2015; Quiroz et al. 2004), including the its modulatory efects on GSK-3β and IMPase (Motoi circadian clock rhythm (McCarthy 2019) and the neu- et al. 2014). As several DNA and RNA viruses are able to ral plasticity (Alda 2015). Although a detailed review of inhibit the autophagy pathway to increase their survival lithium molecular efects lies outside the scope of this (Mehrbod et al. 2019), this molecular efect of lithium review, some mechanisms might be relevant with regard may decrease the chance of the viruses’ survival. to its antiviral efects: [a] the inhibition of the phosphati- Finally, the relevant inhibitory action of lithium on dylinositol signalling pathway via suppression of the ino- GSK-3ß, a serine-threonine kinase that infuences more sitol-polyphosphate 1-phosphatase (IPPase) and inositol than one hundred substrates modulating cell survival, monophosphate phosphatase (IMPase) (Yu and Green- gene expression and microtubule formation, appears rel- berg 2016), [b] the regulation of autophagy (Motoi et al. evant (Alda 2015; Quiroz et al. 2014). In fact, the inhibi- 2014), and [c] the inhibition of the glycogen synthase tion of GSK-3ß during the later stages of infection with kinase-3, isoform β (GSK-3β) (Quiroz et al. 2004). Dengue virus-2 (DENV-2), an RNA virus, resulted in a Experimental evidence shows that both IMPase and reduction of viral titres in hepatocarcinoma cell (Huh-7) IPPase, which are members of a group of at least four and Vero cell lines (Cuartas-López and Gallego-Gómez magnesium-dependent phosphomonoesterases, are 2020). In addition, lithium-induced inhibition of GSK- signifcantly inhibited at therapeutic serum concentra- 3ß led to a signifcantly more decreased production of tions of lithium (0.6–1.2 mM/l) (Quiroz et al. 2004). chronic hepatitis C virus (HCV) viral particles in treated Inositol is the essential substrate for the synthesis of vs. untreated human hepatoma cell lines (Sarhan et al. phosphatidylinositol (PI), from which PI(4,5) biphos- 2017). phate (P2) is produced (Yu and Greenberg 2016). With the receptor-mediated activation of the phospholipase Lithium and immune system C (PLC), PI(4,5)P2 is cleaved to form inositol-1,4,5- triphosphates (IP3) and 1,2-diacylglycerol (DAG) (Streb Immune dysfunction seems to plays a key role in the et al. 1983). Te IP3 can be either recycled to myo- onset and progression of BD in a substantial propor- inositol by a series of dephosphorylations catalysed by tion of individuals (Rosenblat 2019). Lithium has long IPPase and IMPase or, alternatively, can be phosphoryl- been recognized as an immune modulating drug (Ryba- ated sequentially to form IP4, IP5, IP6, IP7 and IP8 by a kowski 1999), with both anti-infammatory (e.g., sup- series of kinases, including the inositol polyphosphate pression of cyclooxygenase-2 expression, inhibition of multikinase (IPMK) and inositol pentakisphosphate interleukin (IL)-1β and tumour necrosis factor-α pro- 2-kinase (IPPK) (Balla 2013; Wei et al. 2018; Yu and duction, and enhancement of IL-2 and IL-10 synthesis) Greenberg 2016). Te depletion of myoinositol deter- and pro-infammatory (e.g., induction of IL-4, IL-6 and mined by the lithium-induced inhibition of IMPase other pro-infammatory cytokines synthesis) action (Nas- and IPPase, could in turn provoke the dampening of sar and Azab 2014). In the long term, however, the use PI signalling with decreased downstream levels of ino- of lithium has been signifcantly associated with a nor- sitol phosphates. Although experimental data suggest malization of cytokine levels, balancing the disruptions that long-term, rather than short-term, lithium expo- observed in BD patients (Van Den Ameele et al. 2016). sure can dampen PI signalling (Wei et al. 2018), this Terefore, lithium exerts a combined action that involves molecular efect if of great interest in terms of potential multiple pathways. Tis discloses diferent potential antiviral efects. Indeed, IP6 appears to be a key factor applications of lithium which remain largely unexplored in substantially increasing the viral stability of HIV, an (Chiu et al. 2013). Murru et al. Int J Bipolar Disord (2020) 8:21 Page 3 of 9 Aim of the review also to pseudorabies and vaccinia virus (Skinner et al.
Recommended publications
  • Key Factors That Enable the Pandemic Potential of RNA Viruses and Inter-Species Transmission: a Systematic Review
    viruses Review Key Factors That Enable the Pandemic Potential of RNA Viruses and Inter-Species Transmission: A Systematic Review Santiago Alvarez-Munoz , Nicolas Upegui-Porras , Arlen P. Gomez and Gloria Ramirez-Nieto * Microbiology and Epidemiology Research Group, Facultad de Medicina Veterinaria y de Zootecnia, Universidad Nacional de Colombia, Bogotá 111321, Colombia; [email protected] (S.A.-M.); [email protected] (N.U.-P.); [email protected] (A.P.G.) * Correspondence: [email protected]; Tel.: +57-1-3-16-56-93 Abstract: Viruses play a primary role as etiological agents of pandemics worldwide. Although there has been progress in identifying the molecular features of both viruses and hosts, the extent of the impact these and other factors have that contribute to interspecies transmission and their relationship with the emergence of diseases are poorly understood. The objective of this review was to analyze the factors related to the characteristics inherent to RNA viruses accountable for pandemics in the last 20 years which facilitate infection, promote interspecies jump, and assist in the generation of zoonotic infections with pandemic potential. The search resulted in 48 research articles that met the inclusion criteria. Changes adopted by RNA viruses are influenced by environmental and host-related factors, which define their ability to adapt. Population density, host distribution, migration patterns, and the loss of natural habitats, among others, have been associated as factors in the virus–host interaction. This review also included a critical analysis of the Latin American context, considering its diverse and unique social, cultural, and biodiversity characteristics. The scarcity of scientific information is Citation: Alvarez-Munoz, S.; striking, thus, a call to local institutions and governments to invest more resources and efforts to the Upegui-Porras, N.; Gomez, A.P.; study of these factors in the region is key.
    [Show full text]
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • On the Coronaviruses and Their Associations with the Aquatic Environment and Wastewater
    water Review On the Coronaviruses and Their Associations with the Aquatic Environment and Wastewater Adrian Wartecki 1 and Piotr Rzymski 2,* 1 Faculty of Medicine, Poznan University of Medical Sciences, 60-812 Pozna´n,Poland; [email protected] 2 Department of Environmental Medicine, Poznan University of Medical Sciences, 60-806 Pozna´n,Poland * Correspondence: [email protected] Received: 24 April 2020; Accepted: 2 June 2020; Published: 4 June 2020 Abstract: The outbreak of Coronavirus Disease 2019 (COVID-19), a severe respiratory disease caused by betacoronavirus SARS-CoV-2, in 2019 that further developed into a pandemic has received an unprecedented response from the scientific community and sparked a general research interest into the biology and ecology of Coronaviridae, a family of positive-sense single-stranded RNA viruses. Aquatic environments, lakes, rivers and ponds, are important habitats for bats and birds, which are hosts for various coronavirus species and strains and which shed viral particles in their feces. It is therefore of high interest to fully explore the role that aquatic environments may play in coronavirus spread, including cross-species transmissions. Besides the respiratory tract, coronaviruses pathogenic to humans can also infect the digestive system and be subsequently defecated. Considering this, it is pivotal to understand whether wastewater can play a role in their dissemination, particularly in areas with poor sanitation. This review provides an overview of the taxonomy, molecular biology, natural reservoirs and pathogenicity of coronaviruses; outlines their potential to survive in aquatic environments and wastewater; and demonstrates their association with aquatic biota, mainly waterfowl. It also calls for further, interdisciplinary research in the field of aquatic virology to explore the potential hotspots of coronaviruses in the aquatic environment and the routes through which they may enter it.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Topical Pharmaceutical Compositions
    Europâisches Patentamt 0 085 579 ® ê European Patent Office @ Publication number: B1 Office européen des brevets ® EUROPEAN PATENT SPECIFICATION @ Date of publication of patent spécification: 06.05.87 ® Intel.4: A 61 K 45/06, A 61 K 31/195, A 61 K 31/20, A 61 K 31/375, (H) Application number: 83300531.7 A 61 K 31/585, A 61 K 31/19, © Date offiling: 02.02.83 A 61 K 31/61, A 61 K 31/355, A 61 K 31/715, A 61 K 33/30, A 61 K 35/78 (54) Topical pharmaceutical compositions. (§) Priority: 03.02.82 US 345204 (73) Proprietor: EFAMOL LIMITED 12th Floor Moor House London Wall London EC2Y 5HE (GB) (§) Date of publication of application: 10.08.83 Bulletin 83/32 ® Inventor: Horrobin, David Frederick P.O.Box 10 Nuns Island (§) Publication of the grant of the patent: Montréal H3E 1 J8 (CA) 06.05.87 Bulletin 87/19 Inventor: Lieb, Julian 41 Village Lane Bethany Connecticut 06525 (US) (S) Designated Contracting States: AT BE CH DE FR GB IT Ll LU NL SE (74) Représentative: Cockbain, Julian Roderick Michaelson et al - (§) Références cited: Frank B. Dehn & Co. European Patent Attorneys EP-A-0 068854 Impérial House 15-19, Kingsway US-A-3 639 625 London WC2B 6UZ (GB) US-A-4328243 CÛ O) in LO oo o o Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted.
    [Show full text]
  • Alphabetical Listing of ATC Drugs & Codes
    Alphabetical Listing of ATC drugs & codes. Introduction This file is an alphabetical listing of ATC codes as supplied to us in November 1999. It is supplied free as a service to those who care about good medicine use by mSupply support. To get an overview of the ATC system, use the “ATC categories.pdf” document also alvailable from www.msupply.org.nz Thanks to the WHO collaborating centre for Drug Statistics & Methodology, Norway, for supplying the raw data. I have intentionally supplied these files as PDFs so that they are not quite so easily manipulated and redistributed. I am told there is no copyright on the files, but it still seems polite to ask before using other people’s work, so please contact <[email protected]> for permission before asking us for text files. mSupply support also distributes mSupply software for inventory control, which has an inbuilt system for reporting on medicine usage using the ATC system You can download a full working version from www.msupply.org.nz Craig Drown, mSupply Support <[email protected]> April 2000 A (2-benzhydryloxyethyl)diethyl-methylammonium iodide A03AB16 0.3 g O 2-(4-chlorphenoxy)-ethanol D01AE06 4-dimethylaminophenol V03AB27 Abciximab B01AC13 25 mg P Absorbable gelatin sponge B02BC01 Acadesine C01EB13 Acamprosate V03AA03 2 g O Acarbose A10BF01 0.3 g O Acebutolol C07AB04 0.4 g O,P Acebutolol and thiazides C07BB04 Aceclidine S01EB08 Aceclidine, combinations S01EB58 Aceclofenac M01AB16 0.2 g O Acefylline piperazine R03DA09 Acemetacin M01AB11 Acenocoumarol B01AA07 5 mg O Acepromazine N05AA04
    [Show full text]
  • Coronavirus: Detailed Taxonomy
    Coronavirus: Detailed taxonomy Coronaviruses are in the realm: Riboviria; phylum: Incertae sedis; and order: Nidovirales. The Coronaviridae family gets its name, in part, because the virus surface is surrounded by a ring of projections that appear like a solar corona when viewed through an electron microscope. Taxonomically, the main Coronaviridae subfamily – Orthocoronavirinae – is subdivided into alpha (formerly referred to as type 1 or phylogroup 1), beta (formerly referred to as type 2 or phylogroup 2), delta, and gamma coronavirus genera. Using molecular clock analysis, investigators have estimated the most common ancestor of all coronaviruses appeared in about 8,100 BC, and those of alphacoronavirus, betacoronavirus, gammacoronavirus, and deltacoronavirus appeared in approximately 2,400 BC, 3,300 BC, 2,800 BC, and 3,000 BC, respectively. These investigators posit that bats and birds are ideal hosts for the coronavirus gene source, bats for alphacoronavirus and betacoronavirus, and birds for gammacoronavirus and deltacoronavirus. Coronaviruses are usually associated with enteric or respiratory diseases in their hosts, although hepatic, neurologic, and other organ systems may be affected with certain coronaviruses. Genomic and amino acid sequence phylogenetic trees do not offer clear lines of demarcation among corona virus genus, lineage (subgroup), host, and organ system affected by disease, so information is provided below in rough descending order of the phylogenetic length of the reported genome. Subgroup/ Genus Lineage Abbreviation
    [Show full text]
  • Modelling the Thermal Inactivation of Viruses from the Coronaviridae Family in Suspensions Or on Surfaces with Various Relative Humidities
    medRxiv preprint doi: https://doi.org/10.1101/2020.05.26.20114025; this version posted May 29, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Modelling the thermal inactivation of viruses from the Coronaviridae family in suspensions or on surfaces with various relative humidities. Authors: Laurent Guillier,a Sandra Martin-Latil,b Estelle Chaix,a Anne Thébault,a Nicole Pavio,c Sophie Le Poder,c on behalf of Covid-19 Emergency Collective Expert Appraisal Group,d Christophe Batéjat,e Fabrice Biot,f, Lionel Koch,f Don Schaffner,g Moez Sanaa,a Affiliations: aRisk Assessment Department, French Agency for Food, Environmental and Occupational Health & Safety, 14, rue Pierre et Marie Curie, Maisons‐Alfort, France bLaboratory for food safety French Agency for Food, Environmental and Occupational Health & Safety, University of Paris-EST, Maisons-Alfort, France cUMR Virologie 1161, ENVA, INRAE, Anses, Maisons-Alfort, France dMembership of the Covid-19 Emergency Collective Expert Appraisal Group is provided in the Acknowledgments eUnité Environnement et Risques Infectieux, Cellule d’Intervention Biologique d’Urgence (CIBU), Institut Pasteur, Paris, France fBacteriology Unit, French Armed Forces Biomedical Research Institute (IRBA), Brétigny-sur-Orge, France gDepartment of Food Science, Rutgers University, New Brunswick, NJ, USA Affiliations: Running Head: Modelling the inactivation of coronaviruses on fomites NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
    [Show full text]
  • ACCGE 2015 Abstracts Ebook
    Table of Contents Introduction/Plenary Correlated Electron Crystals 1 Detector Materials: Scintillators and Semiconductors (ACCGE) 1 Fundamentals of Crystal Growth (ACCGE) 1 III-V Nitride, SiC, and Other Wide Bandgap Materials (Joint ACCGE/OMVPE) 1 Second Symposium on 2D Electronic Materials (Joint ACCGE/OMVPE) 1 Correlated Electron Crystals 2 Detector Materials: Scintillators and Semiconductors (ACCGE) 2 Fundamentals of Crystal Growth (ACCGE) 2 III-V Nitride, SiC, and Other Wide Bandgap Materials (Joint ACCGE/OMVPE) 2 Second Symposium on 2D Electronic Materials (Joint ACCGE/OMVPE) 2 Detector Materials: Scintillators and Semiconductors (ACCGE) 3 Fundamentals of Crystal Growth (ACCGE) 3 III-V Nitride, SiC, and Other Wide Bandgap Materials (Joint ACCGE/OMVPE) 3 Second Symposium on 2D Electronic Materials (Joint ACCGE/OMVPE) 3 Poster Session 1 III-Vs on Silicon (Joint ACCGE/OMVPE) 1 Young Author and AACG Awards Detector Materials: Scintillators and Semiconductors (ACCGE) 4 Fundamentals of Crystal Growth (ACCGE) 4 III-Vs on Silicon (Joint ACCGE/OMVPE) 2 Second Symposium on 2D Electronic Materials (Joint ACCGE/OMVPE) 4 III-V Nitride, SiC, and Other Wide Bandgap Materials (Joint ACCGE/OMVPE) 4 Nonlinear Optical and Laser Host Materials (ACCGE) 1 Thin Film Growth, Epitaxy, and Superlattices (Joint ACCGE/OMVPE) 1 Second Symposium on 2D Electronic Materials (Joint ACCGE/OMVPE) 5 III-V Nitride, SiC, and Other Wide Bandgap Materials (Joint ACCGE/OMVPE) 5 Materials for Photovoltaics and Energy Technology (Joint ACCGE/OMVPE) 1 Nonlinear Optical and
    [Show full text]
  • Transcriptome and Coronavirus: New Hope and Therapy
    Review Volume 11, Issue 2, 2021, 9541 - 9552 https://doi.org/10.33263/BRIAC112.95419552 Transcriptome and Coronavirus: New Hope and Therapy Khaled Mohamed Mohamed Koriem 1,* 1 Department of Medical Physiology, Medical Research Division, National Research Centre, 33 El-Buhouth Street, Dokki, Cairo, 12622, Egypt * Correspondence: [email protected]; Scopus Author ID 24477156100 Received: 20.08.2020; Revised: 7.09.2020; Accepted: 9.09.2020; Published: 13.09.2020 Abstract: Transcriptome refers to all RNA particles occur inside one cell or inside numerous cells in one organ. Coronaviruses are a family of correlated viruses that induce viral infection. In humans, coronaviruses induce respiratory viral infections that may be mild or dangerous. The coronavirus shape is large circular elements that have round tip outbreaks - the virus diameter particles=120 nm. The RNA viral genome occurs in coronavirus. The coronavirus genome size = 27-34 kilobases, and this size is the largest RNA genome size. The Life cycle of coronavirus includes viral entry, replication, and release. Coronavirus transmission was done through the connection of its protein with host cell receptors in a specific process. There are 4 types of coronavirus genus: (1) Alphacoronavirus, (2) Betacoronavirus, (3) Gammacoronavirus, and (4) Deltacoronavirus. Viral replication, immune evasion, and virion biogenesis correlated with host cell transformation mechanism. Viral molecular mechanism hijacks the host cell protein production mechanism. There is an important host factor (CPSF6) that connects with nuclear protein (NP1). The CPSF6 increases the nuclear production of NP1 in the same time, CPSF6 possesses an important role in the progress of capsid mRNAs inside the nucleus.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2016/0354315 A1 Li (43) Pub
    US 20160354315A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2016/0354315 A1 Li (43) Pub. Date: Dec. 8, 2016 (54) DOSAGE FORMS AND USE THEREOF Publication Classification (71) Applicant: Triastek, Inc., Nanjing (CN) (51) Int. Cl. A69/20 (2006.01) (72) Inventor: Xiaoling Li, Dublin, CA (US) A6IR 9/24 (2006.01) A63L/92 (2006.01) (52) U.S. Cl. (21) Appl. No.: 15/173,596 CPC ........... A61K 9/2031 (2013.01); A61K 9/2027 (2013.01); A61K 31/192 (2013.01); A61 K 9/209 (2013.01) (22) Filed: Jun. 3, 2016 (57) ABSTRACT The present disclosure provides a stable solid pharmaceuti Related U.S. Application Data cal dosage form for oral administration. The dosage form includes a Substrate that forms at least one compartment and (60) Provisional application No. 62/170,645, filed on Jun. a drug content loaded into the compartment. The dosage 3, 2015, provisional application No. 62/313,092, filed form is so designed that the active pharmaceutical ingredient on Mar. 24, 2016. of the drug content is released in a controlled manner. Patent Application Publication Dec. 8, 2016 Sheet 1 of 20 US 2016/0354315 A1 FG. A F.G. B. Peak carcetitration, tax ise F.G. C Patent Application Publication Dec. 8, 2016 Sheet 2 of 20 US 2016/0354315 A1 F.G. 2B Patent Application Publication Dec. 8, 2016 Sheet 3 of 20 US 2016/0354315 A1 F.G. 3 Patent Application Publication Dec. 8, 2016 Sheet 4 of 20 US 2016/0354315 A1 Patent Application Publication Dec.
    [Show full text]
  • COVID-19 and Herpes Simplex Virus Infection: a Cross-Sectional Study
    medRxiv preprint doi: https://doi.org/10.1101/2021.07.09.21260217; this version posted July 12, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. COVID-19 and Herpes Simplex Virus Infection: A Cross-Sectional Study Mohammed Shanshal1, *, Hayder Saad Ahmed2, ᶺ 1 Basildon and Thurrock Hospitals NHS Foundation Trust, Department of Dermatology, UK 2 University of Tikrit, College of Medicine, Department of Dermatology and Venereology, Iraq * Specialist dermatologist, MBChB, FABMS – Dermatology ᶺ Specialist dermatologist, MBChB, FIBMS – Dermatology Corresponding author: Mohammed Shanshal, MBChB, FABMS – Dermatology Specialist Dermatologist at Basildon University Hospital, UK Email: [email protected] ORCID Id: https://orcid.org/0000-0003-2877-5919 Word count: 1292 Abstract word count: 215 Number of figures: 3 Number of tables: 2 Number of references: 36 Conflicts of interest: None Funding sources: None Patient privacy and ethical use of images: The patients in this manuscript have provided written informed consent for the publication of their case details, including the use of images. NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2021.07.09.21260217; this version posted July 12, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
    [Show full text]